Hiroki Tawaratsumida

Dr. Hiroki Tawaratsumida

orcid

Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
30 September 2015 in BMC Musculoskeletal Disorders
Verified
Journal Article
Open access
PDF file
KTKengo Takahashi
Kengo Takahashi
TSTakao Setoguchi
Takao Setoguchi
HTHiroki Tawaratsumida
Hiroki Tawaratsumida
YAYoshiya Arishima
Yoshiya Arishima
HTHiroyuki Tominaga
Hiroyuki Tominaga
SKSetsuro Komiya
Setsuro Komiya
Osteoporosis is a complication of rheumatoid arthritis (RA). We identified risk factors for osteoporosis during treatment with biologics. Femoral neck bone mineral density (BMD) was measured in 186 patients with biologics-treated RA. We compared the characteristics of those with BMD ≥70 % of young adult mean (YAM) and those with BMD <70 % of YAM, and undertook multivariable logistic regression analysis to identify risk factors for bone loss. Mean age and disease duration, the proportion of females, scores in the Modified Health Assessment Questionnaire and history of vertebral fracture were significantly greater in the BMD <70 % of YAM group, but body mass index (BMI) was significantly lower in the BMD <70 % of YAM group. There was no significant difference between the groups in terms of other biomarkers of RA activity, the proportion treated with methylprednisolone, or the duration or choice of biologics. The proportions of patients treated with anti-osteoporosis drugs and parathyroid hormone were significantly higher in the BMD <70 % of YAM group. In the multivariable analysis, advanced age, female, longer disease duration, history of past thoracic or lumbar vertebral fracture, higher Steinbrocker classification and lower BMI were significant factors for BMD <70 % of YAM. We identified risk factors for bone loss in patients with RA treated with biologics. Before suppression of disease activity by biologics, bone loss might already be advanced. We recommend that patients with RA who possess these risk factors be considered for earlier and more intense treatment to prevent bone loss, as well as addressing RA disease progression.

21 December 2017 in BMC Research Notes
Verified
Journal Article
Open access
PDF file
HTHiroki Tawaratsumida
Hiroki Tawaratsumida
TSTakao Setoguchi
Takao Setoguchi
YAYoshiya Arishima
Yoshiya Arishima
HOHideo Ohtsubo
Hideo Ohtsubo
MAMasaki Akimoto
Masaki Akimoto
SKSetsuro Komiya
Setsuro Komiya
Osteoporosis is a complication of rheumatoid arthritis. We examined the risk factors for bone loss in rheumatoid arthritis patients receiving biological disease-modifying anti-rheumatic drugs. Lumbar spine and femoral neck bone mineral density was measured at two time points in 153 patients with rheumatoid arthritis managed with biological disease-modifying anti-rheumatic drugs. We examined patients’ variables to identify risk factors for least significant reduction of bone mineral density. Least significant reduction of lumbar spine bone mineral density (≤ − 2.4%) was seen in 13.1% of patients. Least significant reduction of femoral neck bone mineral density (≤ − 1.9%) was seen in 34.0% of patients. Multiple logistic regression analysis showed that a risk factor for least significant reduction of the lumbar spine was high-dose methylprednisolone use. Multiple regression analysis showed that a risk factor for least significant reduction of the femoral neck was short disease duration. Our findings showed that a risk factor for femoral neck bone mineral density reduction was a short disease duration. These findings suggest that rheumatoid arthritis patients receiving treatment with biological disease-modifying anti-rheumatic drugs may benefit from earlier osteoporosis treatments to prevent femoral neck bone loss.

15 August 2024 in Osteoarthritis and Cartilage
Verified
Journal Article
Open access
HTHiroki Tawaratsumida
Hiroki Tawaratsumida
TITomohiro Iuchi
Tomohiro Iuchi
YMYusuke Masuda
Yusuke Masuda
TITakayuki Ide
Takayuki Ide
SMShingo Maesako
Shingo Maesako
NTNoboru Taniguchi
Noboru Taniguchi
Objective: To evaluate the humeral head bone volume of patients with cuff tear arthropathy (CTA) and examine the therapeutic effect of zoledronate in a rat modified model of CTA (mCTA). Design: The bone mass in patients with CTA was measured using Hounsfield units from CT images. The mCTA was induced by transecting the rotator cuff, biceps brachii tendon, and superior half of the joint capsule in adult rat shoulders. A single subcutaneous injection of zoledronate was followed by bone histomorphometry and immunohistochemistry of the humeral head, as well as the Murine Shoulder Arthritis Score (MSAS) assessment. Results: The humeral head bone volume was decreased in patients with CTA. In the mCTA model, M1 macrophages were increased in the synovium and were decreased by zoledronate treatment. The increased expressions of TNF-alpha, IL-1 beta and IL-6 in mCTA synovium and articular cartilage were suppressed in the zoledronate-treated mCTA group. The expression of catabolic enzymes in the articular cartilage and MSAS showed similar results. The zoledronate-treated mCTA group showed a decreased subchondral bone collapse with a decreased RANKL/OPG expression ratio and a suppressed number of osteoclasts compared with the control mCTA group. The enhanced expressions of HMGB1 and S100A9 in the mCTA shoulders were eliminated in the zoledronate-treated mCTA group. Conclusions: The humeral head subchondral bone was decreased in patients with CTA. In the mCTA model, the collapse and osteoarthritic changes were prevented by zoledronate administration. Zoledronate seemed to suppress the number of M1 macrophages in the synovium and osteoclasts in the subchondral bone. (c) 2024 The Author(s). Published by Elsevier Ltd on behalf of Osteoarthritis Research Society International. This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).

6 October 2026 in Osteoarthritis and Cartilage Open
Verified
Journal Article
Open access
TITomohiro Iuchi
Tomohiro Iuchi
KSKento Shimanoe
Kento Shimanoe
TITakayuki Ide
Takayuki Ide
STSeiya Takada
Seiya Takada
SSSuguru Saho
Suguru Saho
NTNoboru Taniguchi
Noboru Taniguchi
To characterize bone morphogenetic protein (BMP) signaling in cuff tear arthropathy (CTA) using a modified rat model (mCTA) and determine whether inhibition of DMH1-sensitive BMP type I receptor signaling attenuates CTA pathology. The rat mCTA model was generated by resection of the supraspinatus and infraspinatus tendons, the superior joint capsule, and the long head of the biceps tendon. Single-cell RNA sequencing (scRNA-seq) was performed to characterize BMP ligand expression in the humeral head. BMP-2, BMP-7, and phosphorylated Smad1/5 (p-Smad1/5) were evaluated by immunohistochemistry, and Id1 expression was assessed by RT-qPCR. Synovial macrophage subsets were assessed by immunostaining. Rats received daily intraperitoneal DMH1 (10 mg/kg) or vehicle for 4 weeks. Histological scores, bone volume, osteoclast number, inflammatory cytokines, catabolic enzymes, and macrophage markers were quantified. scRNA-seq revealed expression of BMP ligands. In mCTA cartilage, BMP-2 and BMP-7 expression, p-Smad1/5 signaling, and hypertrophic markers (Runx2, Col10a1) were upregulated. DMH1 suppressed Smad1/5 activation, reduced inflammatory and catabolic gene expression, and attenuated cartilage degeneration. In subchondral bone, BMP signaling was associated with increased osteoclast numbers, RANKL/OPG imbalance, and reduced bone volume, all of which were improved by DMH1 treatment. In the synovium, BMP signaling and inflammatory mediators were elevated with increased macrophage numbers; DMH1 reduced inflammatory mediators and M1 macrophage numbers. BMP-Smad1/5 signaling is activated in multiple joint tissues in mCTA and is associated with cartilage degeneration, subchondral bone resorption, and synovial inflammation. These findings suggest that BMP-Smad1/5 signaling may contribute to the pathological changes observed in mCTA.

2 October 2026 in Bone & Joint Research
Verified
Journal Article
Open access
PDF file
TITakayuki Ide
Takayuki Ide
YMYusuke Masuda
Yusuke Masuda
KSKento Shimanoe
Kento Shimanoe
SSSuguru Saho
Suguru Saho
STSeiya Takada
Seiya Takada
NTNoboru Taniguchi
Noboru Taniguchi
Aims: Enhanced osteoclast activity in subchondral bone is implicated in osteoarthritis (OA) progression, but the contribution of osteoclasts versus synovial inflammation in cuff tear arthropathy (CTA) remains unclear. This study investigated whether inhibition of osteoclasts using an anti-receptor activator of nuclear factor κB ligand (RANKL) antibody can suppress joint degeneration in a mouse CTA model without affecting synovial inflammation. Methods: A modified CTA (mCTA) model was established in mice by resecting the supraspinatus and infraspinatus tendons, the superior joint capsule, and the long head of the biceps tendon in the right shoulder of C57BL/6J mice. Mice were assigned to four groups: sham or mCTA, each treated with phosphate-buffered saline or anti-RANKL antibody (5 mg/kg subcutaneously every two weeks). Four weeks post-surgery, histological analyses of the humeral head were performed using the Murine Shoulder Arthritis Score (MSAS), immunohistochemistry for osteoclasts, osteoblasts, RANKL/osteoprotegerin (OPG), inflammatory cytokines, and catabolic enzymes, and quantification of synovial M1 macrophages. Subchondral bone volume (BV) was assessed via the bone volume/tissue volume ratio. Results: The mouse mCTA model reproduced clinically relevant CTA phenotypes, including cartilage degeneration, subchondral bone loss, and joint surface collapse, within four weeks. RANKL expression and osteoclast surface increased in the superior and middle zones, while osteoblasts decreased. Synovial RANKL expression was low and unchanged after mCTA surgery. Anti-RANKL antibody administration significantly suppressed osteoclast surface and preserved subchondral BV, leading to attenuation of cartilage degeneration and reduced expression of inflammatory cytokines and catabolic enzymes in cartilage and subchondral bone. The synovitis score, synovial M1 macrophages, and inflammatory factors were unaffected, indicating that suppression of osteoclasts was sufficient to mitigate joint degeneration. Conclusion: Inhibition of subchondral osteoclasts via anti-RANKL antibody reduces CTA-associated cartilage and bone degeneration without altering synovitis. These findings suggest that targeting osteoclasts may represent a promising disease-modifying strategy for CTA, and targeting RANKL with denosumab may prevent or slow shoulder OA progression. Cite this article: Bone Joint Res 2026;15(10):1183–1195.